Podcast

Insights on Purity and Intactness of AAV Gene Therapy Vectors

Author(s):

Vironova

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!
Related Videos
Related Content
Background with viruses. Adeno-associated virus serotype 1. Virus is used as a vector for gene therapy. A model is built using data of viral macromolecular structure from Protein Data Bank (PDB 3NG9) | Image Credit: © Dr_Microbe - © Dr_Microbe - stock.adobe.com
September 11th 2025

AAV Manufacturing Partnership Supports Gene Therapy for CLN2 Batten Disease

Feliza Mirasol
Podcast: Alternative Drug Delivery Methods for Biologics: Where Are We At?
September 11th 2025

Podcast: Alternative Drug Delivery Methods for Biologics: Where Are We At?

Feliza Mirasol
Background with viruses. Adeno-associated virus serotype 1. Virus is used as a vector for gene therapy. A model is built using data of viral macromolecular structure from Protein Data Bank (PDB 3NG9) | Image credit: © Dr_Microbe - © Dr_Microbe - stock.adobe.com
September 11th 2025

ProBio Launches End-to-End AAV Production at NJ Manufacturing Site

Feliza Mirasol
Site Logo
September 11th 2025

Vaccines and Virus Purification through the Ages

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
September 11th 2025

FDA Approves AAVantgarde’s IND Application for Stargardt Gene Therapy

Susan Haigney
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
September 11th 2025

Cellular Origins, Cell and Gene Therapy Catapult, and Resolution Therapeutics Form CGT Manufacturing Consortium

Susan Haigney
© 2025 MJH Life Sciences

All rights reserved.